Paper42900436PubMed
Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology.
Manjunath V and 4 others. Med Oncol, 2026.
Cite this record
ConductScience Library. Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology. Papers, record 42900436. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42900436
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology.
- Journal
- Med Oncol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-23
Source PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Ehrlich Tumor | Major topic |
| Translational Research, Biomedical | Major topic |
| Precision Medicine | Major topic |
| Medical Oncology | Major topic |
| Systems Biology | Major topic |
| RNA-Induced Silencing Complex | |
| MicroRNAs | |
| Gene Expression Regulation, Neoplastic | |
| Gene Regulatory Networks | |
| Humans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Sanction number: SR/PURSE/2021/81 (G). | This work was supported by Department of Science and Technology funding through the "Promotion of University Research and Scientific Excellence" (PURSE) scheme | PubMed |
Source PubMed
References70
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38611893 | Metformin Loaded Zein Polymeric Nanoparticles to Augment Antitumor Activity against Ehrlich Carcinoma via Activation of AMPK Pathway: D-Optimal Design Optimization, In Vitro Characterization, and In Vivo Study. | Molecules | 2024 | https://conductscience.org/library/papers/38611893 | PubMed |
| 2 | 29567708 | The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. | Science | 2018 | https://conductscience.org/library/papers/29567708 | PubMed |
| 3 | 28187287 | Understanding the Intersections between Metabolism and Cancer Biology. | Cell | 2017 | https://conductscience.org/library/papers/28187287 | PubMed |
| 4 | 29199283 | Am I ready for CRISPR? A user's guide to genetic screens. | Nat Rev Genet | 2018 | https://conductscience.org/library/papers/29199283 | PubMed |
| 5 | 37503323 | Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment. | Front Oncol | 2023 | https://conductscience.org/library/papers/37503323 | PubMed |
| 6 | 40907474 | Novel approaches to clinical trial design in cancer neuroscience. | Neuron | 2025 | https://conductscience.org/library/papers/40907474 | PubMed |
| 7 | 28316699 | Breast cancer and associated factors: a review. | J Med Life | 2015 | https://conductscience.org/library/papers/28316699 | PubMed |
| 8 | 19048064 | Mouse xenograft models vs GEM models for human cancer therapeutics. | Dis Model Mech | 2008 | https://conductscience.org/library/papers/19048064 | PubMed |
| 9 | 32075432 | Complexity in regulating microRNA biogenesis in cancer. | Exp Biol Med (Maywood) | 2020 | https://conductscience.org/library/papers/32075432 | PubMed |
| 10 | 8046698 | Paul Ehrlich--the dawn of immunology. | J R Soc Med | 1994 | https://conductscience.org/library/papers/8046698 | PubMed |
| 11 | 21532838 | MicroRNA: Biogenesis, Function and Role in Cancer. | Curr Genomics | 2010 | https://conductscience.org/library/papers/21532838 | PubMed |
| 12 | 28476144 | Multi-omics approaches to disease. | Genome Biol | 2017 | https://conductscience.org/library/papers/28476144 | PubMed |
| 13 | 31350295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 14 | 38751464 | Features and applications of Ehrlich tumor model in cancer studies: a literature review. | Transl Breast Cancer Res | 2023 | https://conductscience.org/library/papers/38751464 | PubMed |
| 15 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 16 | 31974491 | Nerves in cancer. | Nat Rev Cancer | 2020 | https://conductscience.org/library/papers/31974491 | PubMed |
| 17 | 34605108 | Thymoquinone upregulates miR-125a-5p, attenuates STAT3 activation, and potentiates doxorubicin antitumor activity in murine solid Ehrlich carcinoma. | J Biochem Mol Toxicol | 2021 | https://conductscience.org/library/papers/34605108 | PubMed |
| 18 | 36727483 | Recovering false negatives in CRISPR fitness screens with JLOE. | Nucleic Acids Res | 2023 | https://conductscience.org/library/papers/36727483 | PubMed |
| 19 | 22770212 | Cancer epigenetics: from mechanism to therapy. | Cell | 2012 | https://conductscience.org/library/papers/22770212 | PubMed |
| 20 | 34145435 | Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. | Nat Rev Genet | 2021 | https://conductscience.org/library/papers/34145435 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42900436
GET https://conductscience.org/api/papers/v1/42900436/references?page=2